 | | Vol.10.08 – 3 March, 2021 |
| |
|
|
| Researchers demonstrated that leukemia stem cells, hematopoietic stem cells, and pre-leukemic stem cells could be identified and molecularly profiled by combining single-cell transcriptomics with lineage tracing using both nuclear and mitochondrial somatic variants.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| OTS167 alone or in combination with tyrosine kinase inhibitors were used to investigate the effect of OTS167 on FLT3 signaling and expression in human Fms-like tyrosine kinase 3 (FLT3) mutant acute myeloid leukemia cell lines and primary cells.
[Blood Cancer Journal] |
|
|
|
| The authors found that IL-17RB expression was significantly upregulated in spheroid cells and Lgr5-positive cells from the same tumor tissues of patients with gastric cancer, which was closely correlated with the degree of cancer cell differentiation.
[Oncogene] |
|
|
|
| Scientists investigated the interplay and networking pathways occurring between TGFβ family ligands in regulating stemness in triple negative breast cancer (TNBC). They found that TGFβ stimulation of TNBCs resulted in enhanced tumorsphere formation efficiency and an increased proportion of the highly tumorigenic CD44high/CD24low CSC population.
[Oncogenesis] |
|
|
|
| Researchers investigated the effects of Bruton’s tyrosine kinase (BTK) on oncurrent chemoradiotherapy-resistant oral squamous cell carcinoma tissues (OSCC). The effect of ibrutinib, a first-in-class BTK inhibitor, was tested on stem cell-like OSCC tumorspheres.
[Oncogenesis] |
|
|
|
| Cisplatin and anti-CD133 chimeric antigen receptor T (CAR-T) combination treatment inhibited tumor progression in three different xenograft models with diminished CD133 positive stem cell-like cell infiltration.
[Cancer Immunology Immunotherapy] |
|
|
|
| Investigators found that bortezomib (bort) suppressed cell proliferation and decreased colony formation in human and murine leukemic blasts. Bort reduced the frequency and function of leukemia stem cells, inhibited the progression, and extended the overall survival in mixed‐lineage leukemia‐AF9‐transformed leukemic mice.
[Journal of Cellular and Molecular Medicine] |
|
|
|
| Using tissue microarray sections, immunohistochemistry was performed on 360 PTs. Epithelial and stromal expressions of EZH2, EZR, HMGA2, CD24 and CD44 were evaluated to assess their impact on disease progression and behavior in correlation with clinicopathological parameters.
[Cancer Cell International] |
|
|
|
| The authors developed a 3D culture platform that mimics the metastatic tumor extracellular matrix to effectively increase CSC population in vitro and allow CSC analysis.
[Biomedical Materials] |
|
|
|
|
| Scientists discuss the recent advancements of molecular pathways involving breast cancer cell dissemination, role of chemokine-chemokine receptor networks in disseminated cancer cells (DCCs) migration, DCCs phenotypic heterogeneity and unique genes signatures in tumor dormancy, microenvironmental regulation and specific niches that favors DCCs homing and dormancy.
[Seminars in Cancer Biology] |
|
|
|
| The authors discuss recent advances in glioblastoma treatment specifically focused on targeting of glioma stem cells as well as their potential integration into current clinical pathways and trials.
[Frontiers in Oncology] |
|
|
|
|
| Orbus Therapeutics, Inc. announced a positive outcome of the pre-planned interim analysis for futility in its Phase III STELLAR clinical study of eflornithine in patients with recurrent anaplastic astrocytoma.
[Orbus Therapeutics, Inc.] |
|
|
|
| The National Marrow Donor Program®/Be The Match® announced plans to launch the ACCESS clinical trial titled “A Multicenter Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies.”
[The National Marrow Donor Program®] |
|
|
|
|
| April 12 – 14, 2021
Virtual |
|
|
|
|
|
| | Cancer Research Center of Lyon – Lyon, France |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | University of Notre Dame – Notre Dame, Indiana, United States |
|
|
|
| | The Wistar Institute – Philadelphia, Pennsylvania, United States |
|
|
|
| | The Francis Crick Institute – London, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
